DNMTi in Overcoming Immunosuppression in Glioblastoma: Mechanisms and Therapeutic Potential
DOI:
https://doi.org/10.54097/3pzs2n96Keywords:
Glioblastoma, Epigenetics, DNA methylation, Drug resistance.Abstract
Glioblastoma (GBM) is the most aggressive primary malignancy of the central nervous system, characterized by poor prognosis and limited therapeutic options. Epigenetic dysregulation, particularly aberrant DNA methylation, plays a pivotal role in glioblastoma pathogenesis by modulating tumor suppressor genes and oncogenes. The corresponding epigenetic writers and erasers, DNA methyltransferases (DNMTs) and ten-eleven translocation (TET) enzymes, maintain methylation homeostasis, and alterations in their activity can cause abnormal gene expression that drive glioblastoma progression. DNMT1 preserves methylation patterns during DNA replication, whereas DNMT3A and DNMT3B establish de novo methylation. The glioma CpG island methylator phenotype (G-CIMP), an epigenetic subtype of glioblastoma, is frequently associated with mutations in isocitrate dehydrogenase 1 and 2 (IDH1/2), which impair TET-mediated demethylation and result in widespread hypermethylation. Moreover, altered methylation contributes to drug resistance, exemplified by temozolomide (TMZ) resistance mediated through SNHG12 hypomethylation. Currently, two DNMT inhibitors, 5-azacytidine and decitabine, are FDA-approved for certain cancers, while several novel agents, including zebularine, hydralazine and MA17, are under investigation. Although these emerging drugs show promise, their clinical utility remains limited by issues of stability, cytotoxicity and therapy resistance. Understanding the interplay between DNA methylation, tumor progression, and therapy resistance is important to develop new precision medicine strategies in glioblastoma.
Downloads
References
[1] N. F. Brown et al., “Survival Outcomes and Prognostic Factors in Glioblastoma,” Cancers (Basel), vol. 14, no. 13, p. 3161, June 2022, doi: 10.3390/cancers14133161.
[2] D. N. Louis et al., “The 2021 WHO Classification of Tumors of the Central Nervous System: a summary,” Neuro Oncol, vol. 23, no. 8, pp. 1231–1251, Aug. 2021, doi: 10.1093/neuonc/noab106.
[3] K. H. Wood and Z. Zhou, “Emerging Molecular and Biological Functions of MBD2, a Reader of DNA Methylation,” Front. Genet., vol. 7, May 2016, doi: 10.3389/fgene.2016.00093.
[4] M. Okuwaki and A. Verreault, “Maintenance DNA Methylation of Nucleosome Core Particles,” Journal of Biological Chemistry, vol. 279, no. 4, pp. 2904–2912, Jan. 2004, doi: 10.1074/jbc.M310111200.
[5] G. Rajendran, K. Shanmuganandam, A. Bendre, D. Mujumdar, A. Goel, and A. Shiras, “Epigenetic regulation of DNA methyltransferases: DNMT1 and DNMT3B in gliomas,” J Neurooncol, vol. 104, no. 2, pp. 483–494, Sept. 2011, doi: 10.1007/s11060-010-0520-2.
[6] A. J. Tsung et al., “Methylation regulates HEY1 expression in glioblastoma,” Oncotarget, vol. 8, no. 27, pp. 44398–44409, July 2017, doi: 10.18632/oncotarget.17897.
[7] F. Chédin, “The DNMT3 Family of Mammalian De Novo DNA Methyltransferases,” in Progress in Molecular Biology and Translational Science, vol. 101, Elsevier, 2011, pp. 255–285. doi: 10.1016/B978-0-12-387685-0.00007-X.
[8] Z.-M. Zhang et al., “Structural basis for DNMT3A-mediated de novo DNA methylation,” Nature, vol. 554, no. 7692, pp. 387–391, Feb. 2018, doi: 10.1038/nature25477.
[9] S. Tajima, I. Suetake, K. Takeshita, A. Nakagawa, and H. Kimura, “Domain Structure of the Dnmt1, Dnmt3a, and Dnmt3b DNA Methyltransferases,” Adv Exp Med Biol, vol. 1389, pp. 45–68, 2022, doi: 10.1007/978-3-031-11454-0_3.
[10] A. Jeltsch et al., “Mechanism and biological role of Dnmt2 in Nucleic Acid Methylation,” RNA Biology, vol. 14, no. 9, pp. 1108–1123, Sept. 2017, doi: 10.1080/15476286.2016.1191737.
[11] F. Lyko, “The DNA methyltransferase family: a versatile toolkit for epigenetic regulation,” Nat Rev Genet, vol. 19, no. 2, pp. 81–92, Feb. 2018, doi: 10.1038/nrg.2017.80.
[12] D. Bloniarz, J. Adamczyk-Grochala, A. Lewinska, and M. Wnuk, “The lack of functional DNMT2/TRDMT1 gene modulates cancer cell responses during drug-induced senescence,” Aging, vol. 13, no. 12, pp. 15833–15874, June 2021, doi: 10.18632/aging.203203.
[13] J. Dejaegher et al., “DNA methylation based glioblastoma subclassification is related to tumoral T-cell infiltration and patient survival,” Neuro-Oncology, vol. 23, no. 2, pp. 240–250, Feb. 2021, doi: 10.1093/neuonc/noaa247.
[14] T. M. Malta et al., “Glioma CpG island methylator phenotype (G-CIMP): biological and clinical implications,” Neuro-Oncology, vol. 20, no. 5, pp. 608–620, Apr. 2018, doi: 10.1093/neuonc/nox183.
[15] S. Han et al., “IDH mutation in glioma: molecular mechanisms and potential therapeutic targets,” Br J Cancer, vol. 122, no. 11, pp. 1580–1589, May 2020, doi: 10.1038/s41416-020-0814-x.
[16] J. W. Park, K. Lee, E. E. Kim, S.-I. Kim, and S.-H. Park, “Brain Tumor Classification by Methylation Profile,” Journal of Korean Medical Science, vol. 38, no. 43, Sept. 2023, doi: 10.3346/jkms.2023.38.e356.
[17] M. Tompa, B. Kajtar, B. Galik, A. Gyenesei, and B. Kalman, “DNA methylation and protein expression of Wnt pathway markers in progressive glioblastoma,” Pathology - Research and Practice, vol. 222, p. 153429, June 2021, doi: 10.1016/j.prp.2021.153429.
[18] S. Lehtipuro, M. Nykter, and K. J. Granberg, “Modes of immunosuppression in glioblastoma microenvironment,” Oncotarget, vol. 10, no. 9, pp. 920–921, Jan. 2019, doi: 10.18632/oncotarget.26643.
[19] X. Jiang et al., “DNA methylation-regulated YTHDF2 correlates with cell migration and immune cell infiltration in glioma,” Aging, vol. 14, no. 19, pp. 7774–7793, June 2022, doi: 10.18632/aging.204104.
[20] Z. Guo, Q. Huang, Z. Cui, C. Yang, and L. Yang, “Targeting YTHDF2 with pH-responsive siRNA nanoparticles suppresses MYC m6A modification and restores antitumor immunity in hepatocellular carcinoma,” J Nanobiotechnology, vol. 23, no. 1, p. 469, July 2025, doi: 10.1186/s12951-025-03538-0.
[21] A. Gnyszka, Z. Jastrzębski, and S. Flis, “DNA Methyltransferase Inhibitors and Their Emerging Role in Epigenetic Therapy of Cancer,” Anticancer Research, vol. 33, no. 8, pp. 2989–2996, Aug. 2013.
[22] X. Yang, F. Lay, H. Han, and P. A. Jones, “Targeting DNA methylation for epigenetic therapy,” Trends Pharmacol Sci, vol. 31, no. 11, pp. 536–546, Nov. 2010, doi: 10.1016/j.tips.2010.08.001.
[23] M. S. Tomar, A. Kumar, C. Srivastava, and A. Shrivastava, “Elucidating the mechanisms of Temozolomide resistance in gliomas and the strategies to overcome the resistance,” Biochim Biophys Acta Rev Cancer, vol. 1876, no. 2, p. 188616, Dec. 2021, doi: 10.1016/j.bbcan.2021.188616.
[24] M. Weller et al., “MGMT promoter methylation in malignant gliomas: ready for personalized medicine?,” Nat Rev Neurol, vol. 6, no. 1, pp. 39–51, Jan. 2010, doi: 10.1038/nrneurol.2009.197.
[25] W. Kan et al., “Downregulated the expression of DNMT3B by suppressing PI3K/Akt signaling pathway and enhances the chemosensitivity of glioblastoma to temozolomide.,” Oct. 03, 2023, Research Square. doi: 10.21203/rs.3.rs-3358904/v1.
[26] Y. Zhang, H. Zhao, W. Deng, J. Lai, K. Sang, and Q. Chen, “Zebularine potentiates anti-tumor immunity by inducing tumor immunogenicity and improving antigen processing through cGAS-STING pathway,” Commun Biol, vol. 7, no. 1, p. 587, May 2024, doi: 10.1038/s42003-024-06271-w.
[27] M. J. Ruiz-Magaña, R. Martínez-Aguilar, E. Lucendo, D. Campillo-Davo, K. Schulze-Osthoff, and C. Ruiz-Ruiz, “The antihypertensive drug hydralazine activates the intrinsic pathway of apoptosis and causes DNA damage in leukemic T cells,” Oncotarget, vol. 7, no. 16, p. 21875, Mar. 2016, doi: 10.18632/oncotarget.7871.
[28] C. W. Wee et al., “Radiosensitization of Glioblastoma Cells by a Novel DNA Methyltransferase-inhibiting Phthalimido-Alkanamide Derivative,” Anticancer Res, vol. 39, no. 2, pp. 759–769, Feb. 2019, doi: 10.21873/anticanres.13173.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
